FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA ... - Merck
Aug 11, 2021 · KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCC. Based on Phase 3 CLEAR/KEYNOTE-581 Trial, KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib.
FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® …
Jul 22, 2021 · Treatment with LENVIMA plus KEYTRUDA continued until Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined progression of disease as verified by blinded independent central review (BICR), unacceptable toxicity, or for KEYTRUDA, a …
FDA D.I.S.C.O. Burst: Lenvima in combination with Keytruda
On August 10, 2021, FDA approved the combination of lenvatinib (brand name Lenvima) plus pembrolizumab (brand name Keytruda) for first-line treatment of adult patients with advanced renal...
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in …
Sep 17, 2024 · After a median follow-up of 25.6 months (range, 12.6-43.5), LENVIMA plus KEYTRUDA in combination with TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.51-0.84]; p=0.0002) compared to TACE alone.
Merck's Keytruda-Lenvima pair wins one in liver cancer subtype
Sep 14, 2024 · Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer. Meanwhile, Lenvima as a single agent has shown some activity in intermediate-stage liver...
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) …
May 26, 2023 · After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial. Final results will be presented at ASCO 2023 in an oral abstract session. For Print （228KB）.
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA ... - Merck
Jul 22, 2021 · KEYTRUDA, in combination with LENVIMA, is indicated for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
LENVIMA (R) (lenvatinib) Plus KEYTRUDA (R) (pembrolizumab) in …
Sep 17, 2024 · KEYTRUDA is approved as a monotherapy for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1- containing regimen in the...
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA ...
Apr 7, 2023 · KEYTRUDA plus LENVIMA is approved in the U.S., the EU, Japan and other countries for the treatment of advanced renal cell carcinoma (RCC) and certain types of advanced endometrial carcinoma. Lenvatinib is marketed as KISPLYX ® for advanced RCC in the EU.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Jan 19, 2022 · In the Study 111–KEYNOTE-146 trial, 25 treatment with lenvatinib in combination with pembrolizumab had compelling efficacy in patients with previously treated advanced endometrial carcinoma;...
- Some results have been removed